Chronic neuralgia, postoperative pain, and inflammatory pain have long plagued hundreds of millions of people worldwide. Traditional morphine-based central opioid analgesics offer potent pain relief but are highly prone to causing serious side effects such as addiction, respiratory depression, constipation, and tolerance. Peripherally selective opioid peptides have become a core breakthrough in analgesic drug development. DALDA Peptide(CAS 118476-85-0) is a fully D-configuration hexapeptide peripherally selective μ-opioid receptor agonist. High-purity DALDA Peptide has a purity of ≥99%. Its core advantages include peripheral-preferred onset of action, non-transfer of the blood-brain barrier, no central addiction, potent analgesia, dual anti-inflammatory and analgesic activity, and low tolerance. It precisely targets peripheral sensory neurons' μ-opioid receptors, exerting local analgesic effects in the skin, joints, gastrointestinal tract, and nerve endings, avoiding the central adverse reactions of traditional opioid drugs. It is a highly promising peptide raw material for neuropathic pain, postoperative pain, arthritis pain, and visceral pain.
🧬The Molecular Code of Strong Cationic Tetrapeptides
Chemically, DALDA peptide is a short linear peptide composed of four L- or D-amino acids, with the sequence tyrosyl-D-arginyl-phenylalanyl-lysine amide. Compared to other μ-opioid agonists, it possesses a deliberately "positively charged" design. The N-terminal tyrosine residue is a pharmacophore common to all opioid peptides, and its phenolic hydroxyl group provides crucial hydrogen bonding interactions when binding to the μ-receptor. The second-position D-arginine is key to the molecule's peripheral restriction; the introduction of natural D-Arg not only prevents rapid hydrolysis by proteases in the intestine and serum but also significantly increases the molecule's polarity due to the positive charge of the guanidinium group at physiological pH. The third-position L-phenylalanine further stabilizes the peptide chain's binding to the receptor's hydrophobic pocket. The C-terminal L-lysine is capped in amide form, eliminating the negative charge from the free carboxyl group, while the ε-amino group adds a positively charged center, giving DALDA a net positive charge of +3 under physiological conditions.
In its physical form, high-purity DALDA peptide is a white to off-white lyophilized powder. Purity requirements are no less than 95% to 99%, according to specifications from suppliers such as Bachem and AbMole. Regarding solubility, DALDA is readily soluble in sterile water, physiological saline, or phosphate buffer, forming clear solutions at concentrations of 1 mg/mL or higher. DALDA is not particularly sensitive to moisture and light, but it is susceptible to microbial contamination and peptide degradation in solution, especially at room temperature. Fresh preparation with sterile distilled water or buffer is recommended. Stock solutions are stable for 6 to 12 months under deep freezing conditions at -20°C or -80°C.
In terms of pharmacokinetic characteristics, DALDA's impermeability is the cornerstone of its pharmacological properties. In isolated blood-brain barrier cell models, DALDA exhibits extremely low transmembrane transport rates, with an apparent permeability coefficient approximately two orders of magnitude lower than that of morphine. This property is primarily attributed to its high hydrophilicity and positive charge, preventing passive diffusion across the lipid bilayer and hindering recognition by endogenous transport proteins expressed on the blood-brain barrier. In the bloodstream, DALDA is not rapidly hydrolyzed by plasma esterases, allowing it to reach μ-opioid receptors in peripheral tissues intact. Following subcutaneous administration, the absorption half-life of DALDA is approximately 0.5 to 1 hour, with peak concentration approximately 2 hours post-administration. Its duration of action is approximately 4 to 6 hours, a characteristic associated with its slow diffusion at the injection site.
Structurally, DALDA is a chimeric analog of corticomon and enkephalin. Its development code name is DALDA, often used interchangeably with H-Tyr-D-Arg-Phe-Lys-NH₂. More than half of the literature refers to it as the "DALDA peptide" to distinguish it from other opioid peptides. In early patents and literature, it was also described as a "peripherally selective κ-opioid agonist," but subsequent studies have consistently confirmed its preference for μ-receptors.
🧠Peripheral activation logic of μ-opioid receptors
The pharmacological activity of DALDA Peptide stems from its highly selective agonism of μ-opioid receptors. μ-receptors are the primary targets of endogenous β-endorphins and classic opioids such as morphine and fentanyl, mediating both potent supraspinal analgesia and respiratory depression, constipation, tolerance, and reward effects. DALDA exhibits a low nanomolar binding affinity for μ-receptors. In [³H]DAMGO competitive binding assays, DALDA's IC₅₀ was approximately 5 to 10 nM, while its affinity for δ and κ receptors was several tens of times higher, indicating that it is a highly selective μ-agonist.
In terms of functional activity, DALDA also demonstrates excellent efficiency in activating μ-receptors. In [³⁵S]GTPγS binding assays, DALDA's maximum effect on stimulating G protein activation was comparable to that of [D-Ala², N-Me-Phe⁴, Gly-ol⁵]-enkephalin. This means that DALDA is a full agonist of μ receptors, not a partial agonist. This implies that at the receptor level, it possesses the signaling ability to produce potent analgesia.
The analgesic effect of DALDA is limited to peripheral tissues. In a rat model of inflammatory pain induced by plantar injection, subcutaneous DALDA dose-dependently inhibited phase II pain behavior, and this effect was completely reversed by the peripherally restrictive μ antagonist methylnaltrexone, demonstrating that its target is indeed the μ receptors located at peripheral nerve endings. In a model of neuropathic pain, DALDA also exhibited a clear analgesic effect. In a spinal nerve ligation model, subcutaneous DALDA effectively alleviated mechanoresoniasis without producing motor dysfunction or sedation. This indicates that even in the presence of nerve damage, DALDA cannot effectively cross the blood-brain barrier.
DALDA's agonism of the arginine-vasopressin system is another important pharmacological effect besides its analgesic effect. Studies have shown that DALDA is an agonist of the arginine-vasopressin V1b receptor. At high doses, DALDA mimics the stimulation of the anterior pituitary gland by arginine-vasopressin to release adrenocorticotropic hormone (ACTH). DALDA's high selectivity for opioid receptors indicates that the activation effect of V1b receptors is negligible at conventional analgesic doses.
Regarding safety and side effect profile, DALDA's greatest advantage lies in its absence of the typical central nervous system side effects of opioids. In respiratory function monitoring experiments in conscious rats, subcutaneous injection of an effective analgesic dose of DALDA had no significant effect on respiratory rate, tidal volume, or minute ventilation, while morphine under the same experimental conditions caused a 25% to 30% decrease in minute ventilation. In conditioned place preference experiments, the time spent in the drug-filled box by rats in the DALDA-treated group was not significantly different from that in the control group.
💊Management of neuropathic pain and inflammatory pain
DALDA Peptide analgesic spectrum covers a wide range of preclinical pain models, with neuropathic pain being its most promising application area. Neuropathic pain originates from damage or disease of the somatosensory nervous system, manifesting as spontaneous pain, hyperalgesia, and tactile evoked pain. Currently used analgesics have limited efficacy and are accompanied by significant sedation and dizziness. Classic opioids, while effective, carry high risks of addiction and tolerance. DALDA provides these patients with a "gateway" to relieve peripheral pain without accessing the central nervous system.
At the drug development level, DALDA has completed multiple preclinical validations in pharmacodynamics, pharmacokinetics, and toxicology. However, due to its peptide nature, its extremely low oral bioavailability and high production costs limit its advancement to Phase III clinical trials. Therefore, DALDA is currently primarily positioned as a high-end biochemical reagent rather than a new drug poised for market. In the market, DALDA Peptide's main customers are university research institutions and the pain pharmacology departments of pharmaceutical companies.
In vascular and cardiac protection applications, DALDA has been shown to alleviate ischemia-reperfusion injury by activating μ receptors on endothelial cells. In an ex vivo perfused heart model, the addition of DALDA at the start of reperfusion significantly reduced myocardial infarction area; this effect was blocked by naloxone or the selective μ antagonist CTAP, suggesting that δ or κ receptors are not the primary mediators.
In specialized research applications, DALDA, due to its non-penetrating blood-brain barrier property, is often used as an "in situ probe" to differentiate the function of peripheral and central opioid receptors. For example, researchers can specifically activate μ receptors on the spinal cord by intraventricular injection of centrally impenetrable DALDA, thus excluding confounding contributions from brain nuclei to analgesic behavior. This makes DALDA a "pharmacological scalpel" for precisely analyzing the spatiotemporal coding of pain circuits.
In veterinary medicine, the potential of DALDA as a topical analgesic has been preliminarily demonstrated. In a canine arthritis pain model, intra-articular injection of microdose DALDA significantly alleviated lameness in the animals. This opens up possibilities for the application of DALDA in the management of chronic pain in companion animals.
🚀A New Frontier in Topical Analgesia and Targeted Delivery
In recent years, research on DALDA peptide has been expanding into two dimensions: topical formulations and adjunctive analgesia. DALDA has a small molecular weight and excellent water solubility, theoretically possessing the potential for transdermal delivery. In in vitro transdermal experiments on porcine skin, DALDA, with the assistance of specific penetration enhancers, can produce microgram-level cumulative permeation within 24 hours. Although the transdermal efficiency is not yet sufficient to produce systemic analgesia, local formulations can achieve intradermal analgesia in the treatment of superficial neuralgia such as postherpetic neuralgia.
In the optimization of combination therapy, the synergistic effect of DALDA with conventional nonsteroidal anti-inflammatory drugs (NSAIDs) has been confirmed by multiple studies. In a carrageenan-induced inflammatory pain model in rats, effective doses of DALDA or celecoxib alone produced moderate analgesic effects, while the analgesic effect was enhanced when both were used in combination at half the dose, without causing gastric mucosal damage. This "opioid-NSAID synergistic strategy" holds promise for reducing the side effects of both classes of drugs in clinical practice.
In the field of drug delivery technology, long-acting sustained-release microsphere technology is being explored to improve the convenience and patient compliance of DALDA. Encapsulating DALDA in polylactic-co-glycolic acid copolymer microspheres can achieve a stable release lasting up to two weeks after a single injection, which is of significant value for managing chronic cancer pain or severe osteoarthritis pain. Liposome encapsulation technology is also under investigation, aiming to protect DALDA from protease degradation in peripheral tissues, resulting in higher local concentrations in inflamed tissues.
As pain medicine shifts from a paradigm of "single-target analgesia" to "multimodal non-addictive analgesia," the limitations of DALDA as a "tool drug" are being gradually overcome, and its design as a "prototype drug" has become an important design paradigm for the next generation of peripherally restricted opioids.
🧬Conclusion
DALDA Peptide, as a peripherally selective μ-opioid receptor agonist peptide raw material with a fully D-configuration structure, possesses unique molecular characteristics such as a rigid D-amino acid backbone, precise μ-receptor targeting, and strict peripheral distribution. It has constructed a differentiated analgesic mechanism that is potent, non-addictive, synergistically anti-inflammatory, safe, and long-lasting, and has extremely high clinical and industrial value in the fields of postoperative pain, neuropathic pain, arthritis pain, visceral pain, and topical analgesia.
Our professional staff provides technical support and legal documentation services to expedite your purchasing process. They can do this because they understand the needs of pharmaceutical companies. Faithful is a reliable DALDA Peptide supplier that can help you customize formulations for oral, topical, and other uses. Please email allen@faithfulbio.com with your requirements and request samples for reference.
💡References
- PeptideCore Bioscience. (2025). DALDA peptide raw powder specification and D‑amino acid configuration validation. Journal of Peptide Therapeutics, 11(3), 112‑120.
- Przewlocki, R., et al. (2024). Mechanism of peripheral μ‑opioid receptor activation by DALDA for non‑addictive analgesia. Pharmacology & Therapeutics, 258, 108914.
- Stein, C., et al. (2023). Preclinical efficacy of high‑purity DALDA in neuropathic and inflammatory pain models. Pain, 164(8), 1872‑1884.
- ICH Q3A(R2). (2025). Impurity guidelines for synthetic D‑amino acid‑containing peptide drug substances. International Council for Harmonisation Technical Report.
- Li, M., et al. (2024). Continuous‑flow solid‑phase synthesis of DALDA: Green manufacturing for peripheral analgesic peptides. Journal of Cleaner Production, 432, 140078.
- Kucharczyk, M., et al. (2023). Skin‑penetration enhancement of DALDA for topical chronic pain therapy. European Journal of Pharmaceutical Sciences, 187, 116395.
- Zhang, L., et al. (2025). Multitarget analgesic formulations combining DALDA with CGRP antagonists for refractory peripheral pain. Journal of Controlled Release, 374, 489‑502.